Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

Abstract Background TGFβ signaling plays a pleotropic role in tumor biology, promoting tumor proliferation, invasion and metastasis, and escape from immune surveillance. Inhibiting TGFβ’s immune suppressive effects has become of particular interest as a way to increase the benefit of cancer immunoth...

Full description

Bibliographic Details
Main Authors: Rikke B. Holmgaard, David A. Schaer, Yanxia Li, Stephen P. Castaneda, Mary Y. Murphy, Xiaohong Xu, Ivan Inigo, Julie Dobkin, Jason R. Manro, Philip W. Iversen, David Surguladze, Gerald E. Hall, Ruslan D. Novosiadly, Karim A. Benhadji, Gregory D. Plowman, Michael Kalos, Kyla E. Driscoll
Format: Article
Language:English
Published: BioMed Central 2018-06-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
TGF-β receptor I
Antitumor efficacy
Checkpoint inhibitors
Galunisertib
Online Access:http://link.springer.com/article/10.1186/s40425-018-0356-4

Internet

http://link.springer.com/article/10.1186/s40425-018-0356-4

Similar Items